These results suggest that targeting PI3K and NF-kB may be more useful in some cancer cell types than others, and that other factors modulating cIAP expression may be of relevance to the development and maintenance of SMAC mimetic resistance in CLL cells. Here, NFKB1 is linked to B-cell chronic lymphocytic leukemia.